Drug Development · us
IDE849 Plans Pivotal Trials in Neuroendocrine Carcinoma, Pursuing Accelerated and Full Approval in Parallel
Moving from early signals of tumor shrinkage toward testing whether survival can be extended, IDEAYA has outlined a development path for its DLL3-targeted antibody-drug conjugate. However, preliminary FDA feedback does not mean the trial designs or a marketing application have been endorsed.
Patients with neuroendocrine carcinoma that continues to progress after platinum-based chemotherapy have limited subsequent treatment options. Even when a new drug shows signs of tumor shrinkage, questions remain about how long its effects last and whether it can extend life. On November 16, IDEAYA Biosciences announced plans for pivotal trials of IDE849, preparing to explore accelerated approval through a single-arm study while advancing randomized trials to verify longer-term clinical benefit.
IDE849, also known as SHR-4849, is an investigational antibody-drug conjugate (ADC) that links a DLL3-recognizing antibody to a topoisomerase I (TOP1) inhibitor, designed to attack cancer cells expressing DLL3. The development program targets neuroendocrine carcinoma and extensive-stage small cell lung cancer. The announcement describes the company's plans following a Type C meeting with the U.S. Food and Drug Administration (FDA), rather than a marketing approval.
One pathway involves adding a single-arm expansion cohort of approximately 90 patients to the ongoing Phase 1/2 trial, enrolling previously treated patients with gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). The primary endpoint is confirmed objective response rate assessed by blinded independent central review—the proportion of patients whose tumor shrinkage meets specified criteria and is subsequently confirmed—with duration of response providing additional context. The company plans to evaluate two doses, 2.4 and 3.5 milligrams per kilogram, administered intravenously once every three weeks, hoping the results can support an application for accelerated approval.
A parallel randomized Phase 3 confirmatory trial is expected to cover subtypes including GEP-NEC and large cell neuroendocrine carcinoma. The company proposes using progression-free survival to support potential accelerated approval and overall survival to support full approval. It hopes the confirmatory trial will be well advanced, or even fully enrolled, when the single-arm cohort reports its primary results. A separate randomized Phase 3 trial of IDE849 monotherapy in patients with extensive-stage small cell lung cancer previously treated with Imdelltra is also targeted to begin by the end of 2026.
The evidence supporting these plans still comes from small, early-stage studies. In Phase 1 data released by partner Hengrui in October, the objective response rate among 19 patients with neuroendocrine carcinoma was 52.6%, but the confirmed response rate was 36.8%, and median progression-free survival was 7 months. The two response rates should not be conflated. These data provide a basis for further research but are not yet sufficient to demonstrate that IDE849 is superior to existing therapies or that it extends survival.
Safety also requires follow-up in larger populations. According to the company's announcement, among all 122 participants in Hengrui's trial, 8 developed Grade 1–2 interstitial lung disease, and 1 additional participant developed Grade 3 or higher interstitial lung disease. In another global Phase 1/2 trial, Grade 3 or higher treatment-related adverse events occurred in 1 of 20 participants in the 2.4-milligram-per-kilogram dose-expansion group and 4 of 18 participants in the 3.5-milligram-per-kilogram group. The limited samples do not establish a difference in risk between the two doses.
The original announcement and the PR Newswire and BioSpace versions all originated from the company's release; they do not constitute three independent verifications. IDEAYA also explicitly stated that the FDA meeting feedback is preliminary and nonbinding. The agency may subsequently require design changes or additional studies, and may determine that a single-arm study and response rate are insufficient to support accelerated approval. This development makes the path toward approval more concrete. Whether the drug becomes a treatment option still depends on whether subsequent trials can translate early responses into durable, verifiable patient benefit.